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Abstract
Background: Antibodies in adults living in malaria
endemic areas that target specific parasite antigens
are implicated in protective immunity to infection and
disease. This study aimed to identify, isolate and cha-
racterise targets of protective immunity in malaria.
A Plasmodium falciparum antigen termed UB05 (Gen-
bank Accession Number DQ235690: PlasmoDB PF10_
0372) that had been isolated by immunoscreening
with semi-immune sera was studied.
Methods: Polymerase chain reaction, sequencing and
bioinformatics were used to analyse the UB05 gene.
A specific mouse anti-UB05 antibody was used in
parasite reinvasion growth/inhibition assays and in
immunoflourescence to localise the antigen. In a cross-
sectional study, enzyme linked immunosorbent assay
was used to study immunoglobulin G (IgG) responses
to the antigen.
Results: The gene revealed significant homologies
with gene sequences from Plasmodia and other api-
complexan parasites and had two alleles in the wild
P. falciparum isolates. The antigen is expressed by
schizonts and segmented merozoites. Mouse antibod-
ies against it marginally inhibit in vitro invasion of
erythrocytes by P. falciparum. The IgG responses to
UB05 were found to be significantly lower (p-0.05)
in the sera of children (2–5 years) compared with
adults ()18 years), with or without parasitaemia.
However, parasitaemia correlated inversely (rs0.7–
0.75) with serum anti-UB05 IgG concentrations. Fur-
thermore, anti-UB05 IgG concentrations were lower
in the sera of febrile patients (body temperature
)37.58C) than their non-febrile counterparts regard-
less of parasitaemia status.
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Conclusions: These results are compatible with a role
for UB05 in the development of immunity and as a
marker of protective immunity to malaria.
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Introduction
Malaria, a parasitic disease caused by protozoa of the
genus Plasmodium ranks second of the ten top caus-
es of death in Africa (1). It kills 1–3 million children
worldwide every year; 90% of these fatalities occur
among African children. A three-pronged approach
has been recommended for fighting the disease,
namely, rapid detection followed by combination
therapy; the use of mosquito bed nets and targeted
mosquito destruction (2, 3). However, the emergence
and spread of drug and insecticide resistances has
posed serious challenges to these strategies. Hence,
efforts to develop a malaria vaccine remain high on
the international scientific agenda (4). Clinical, epide-
miological and experimental evidence strongly sup-
port the feasibility of a malaria vaccine (5). However,
it has been difficult to construct a sub-unit malaria
vaccine from the leading malaria vaccine candidates
that are currently under intensive investigation (6, 7).
It is possible that all the critical components required
for an effective and long-lasting sub-unit vaccine have
not yet been identified. In fact, although the P. falci-
parum genome codes for nearly 5300 structural
genes, only 40% of these genes are known (8). Con-
ceivably, additional protective antigens remain to be
identified among the unknown gene products. Since
systematic testing of all possible candidates is not
technically feasible, it is necessary to devise app-
roaches for short-listing the candidates that may con-
tribute to protective immunity. One such approach is
differential immuno-screening using sera from semi-
immune and susceptible subjects (9, 10). Antibody
transfer experiments suggest that immunoglobulin G
(IgG) antibodies are critical effectors of protective
immunity to malaria (11, 12). Indeed, many of the
malaria vaccines under investigation are designed to
elicit protective antibodies (7, 13).
Herein, we describe the identification using differ-
ential immuno-screening and molecular cloning of a
dominant antigen termed UB05 (GenBank Accession
Number DQ235690) that was previously listed as a
hypothetical protein (PlasmoDB PF10_0372) of unknown
function on chromosome 10 of the P. falciparum
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genome. We show that UB05 is preferentially recog-
nised by IgG antibodies from semi-immune adults,
and suggest that it may be a marker of immune pro-
tection against malaria.
Materials and methods
Study sites
Most of the studies were carried out at Bolifamba, a small
multi-ethnic trading and farming village of 3500 inhabitants
on the western flank of Mount Cameroon (14). Additional
blood samples were collected at the Kumba Medical
Research station located ;150 km north of Bolifamba.
Study population
Ethical clearance for human population studies was obtained
from the South West Regional Delegation of Public Health.
The study population was comprised of adult volunteers and
children who came to the Malaria Pilot Centre Bolifamba for
consultation, or in response to a general announcement
through the quarter heads in the markets and churches. The
aims of the project were explained to the participants and
informed consent was sought and received from all volun-
teers or their guardians in the cases of minors. Upon recruit-
ment, participants were clinically examined and blood
samples were collected and used for the diagnosis of malar-
ia following previously described standard procedures (14,
15).
Immuno-screening
A P. falciparum 3D7 cDNA expression library (UNI-ZAP XR)
from MR4 (www.mr4.org) was screened using pooled anti-
sera from selected sub-population of participants. The
endemic groups whose sera were used for gene library
screening had been described as susceptible or semi-
immune (15). They comprised 23 infected children (IC)
(1–5 years) and 25 semi-immune adults (18 years or older).
The semi-immune adults included those who had lived in the
high transmission malaria endemic community for at least
5 years, had no reported case of clinical malaria and were
shown by microscopy to remain persistently parasite free for
over 12 months without any chemoprophylaxis. Sera from
these individuals were prepared from whole blood by cen-
trifugation. Pooled high-titre sera for each group were
depleted of anti-Escherichia coli antibodies using E. coli total
proteins coupled to CNBr activated Sepharose-4B following
the manufacturer’s instructions. Prior to screening, the titre
of P. falciparum cDNA library was determined by serially
diluting (10-fold) in SM buffer and plating in order to obtain
a dilution that avoided overlapping plaque formation on the
agar plates. E. coli strain XL-1 Blue MRF (Stratagene, La Jol-
la, California, USA) was infected with the diluted phage
cDNA library, followed by an overnight incubation at 378C or
428C for ;2 h until pinpoint size plaques were visible. The
library was screened using 1:100 dilutions of sera from IC
and partially immune adults following established protocols
(16). Positive plaques specific to partially immune adults
were re-screened at a lower density. This process was
repeated three times until populations of only positive
plaques were obtained.
PCR amplification
Single plaques containing recombinant clones were selected
and transferred to sterile tubes with 100 mL of SM buffer
(100 mM NaCl, 50 mM Tris-HCl at pH 7.5; 10 mM MgSO4).
The agar plugs were incubated in SM buffer overnight at 48C
before being used as templates in the individual PCRs. The
cDNA inserts were amplified using PCR in 50 mL reactions
using the vector-specific primers T3 and T7, as described
previously (17). All PCR reaction products were separated
using 1.5% agarose gels containing ethidium bromide to ver-
ify purity and determine their size. Amplicons were purified
using the Sephaglas bandprep kit (Pharmacia, Uppsala,
Sweden). Each DNA band was eluted with 30 mL of distilled
H2O. For long-term storage, a drop of chloroform was added
to the SM buffer containing pure positive clones.
DNA sequencing and sequence analysis
Freshly purified PCR products of each clone were subcloned
into pCRIITopo-TA vectors as described by the manufacturer
(Invitrogen, Carlsbad, CA, USA). Each cloning reaction was
6 mL in total volume and included 3 mL PCR product, 1 mL
200 mM NaCl; 10 mM MgCl2, 1 mL sterile dH2O and 1 mL
vector. Reaction mixtures were used to directly transform
50 mL. Top10 cells made chemically competent by washing
in cold 100 mM CaCl2 and storing overnight at 48C. Trans-
formed cells were selected by growing on ampicillin plates
and then screened for the presence of inserts by PCR using
T3 and T7 primers and/or the M13 forward and reverse prim-
ers. Positive clones were grown overnight in LB medium and
plasmids prepared using Wizard DNA preparation kit (Pro-
mega, Stockholm, Sweden). Plasmid preparations were
checked for purity using 1% agarose and two separate prep-
arations for each cDNA clone were sequenced commercially
by MWG Biotech (Ebersberg, Germany).
Bioinformatics
Nucleic acid sequences of clones derived with the M13-
reverse primer were transformed into the reverse comple-
ment strand prior to analysis. After editing with VecSreen
National Centre for Biotechnology Information (NCBI) to fil-
ter out vector fragments, the nucleic acid sequences were
compared with public databases (GenBank non-redundant
nucleotide and protein databases) using the BLAST family of
algorithms with default parameters (18, 19). The open read-
ing frames were determined by open reading frame (ORF)-
Finder and conserved-domain searches were performed
using NCBI conserved domain search (20, 21). The ORF
sequences of each clone were also directly analysed against
protein databases at Swisprot and trEMBL. Significant
matches were grouped and analysed for genetic distance
using ClustalW, Phylip and SplitsTree programmes. Homo-
logous sequences were also examined for the number and
length of matching motifs, along with conserved alignment
positions by ClustalW. Predictions of the physicochemical
and structural properties of the derived protein sequences
were performed using the protein analysis software availa-
ble at Expasy.
PCR analysis of field isolates
To further characterise one of the clones, UB05, specific
primers were designed against the ORF of the target
sequence and used to amplify DNA from malaria-infected
blood with PCR. They included: UB05FP-GGCATCCTTCCTT-
TATATGTT and UB05RP-TTATGTGCGTCATCTTTACCT, with
an empirically determined optimum annealing temperature
of 608C. The specificity of the primers was checked by per-
forming a blast search against public DNA databases. DNA
samples that were analysed were extracted from 68 infected
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blood samples collected from patients living in the malaria
endemic rural community of Bolifamba, and from 80 infected
school children around Kumba, Cameroon. DNA templates
for the nested PCR assay were prepared from the whole
blood spot using the simple Chelex-100 (Sigma-Aldrich, St.
Louis, MO, USA) boiling method. Each spot was boiled in
180 mL of Chelex-100 solution and;120 mL of DNA template
was obtained. Five microliter of this was used in the nested
PCR assay.
Prior to UB05 specific PCR, the species of Plasmodium in
each sample was determined using nested PCR following a
previously described protocol (22, 23). PCR products were
analysed on 1.5% agarose gels containing ethidiumbromide.
Amplicons were cut-out, purified, cloned into Topo-TA and
sequenced as described above.
Expression constructs
For cloning into prokaryotic expression vectors, the UB05
ORF was amplified directly from isolated phages with spe-
cific primers spanning the entire ORF, or made to exclude 75
nucleotides at the 59-end coding for the first 25 N-terminal
amino acids. These products were cloned directly into TOPO
expression vectors, pBAD thioTOPO-TA, or pEXP5-NT. The
complete or truncated ORF was also amplified with primers
engineered to have restriction enzyme sites for cloning into
pET32a, pETM11 and pETM-30 E. coli expression vectors. All
recombinant constructs were first amplified in Top10 cells
against appropriate antibiotics. Plasmids, purified as above,
were checked by sequencing before being used for transfor-
mation of expression hosts. Bacteria E. coli host strains test-
ed for expression included Novablue, Top10, BL21, BL21
(DE3)pLys and BLR. Induction conditions with either IPTG or
arabinose were determined empirically and applied as
appropriate.
Expression and purification of recombinant UB05
For high-level expression of UB05 from pEXP5NT, plasmids
were freshly transformed into the appropriate E. coli strain
(BL21(DE3)pLys). A single colony was inoculated into 20 mL
of LB medium with the recommended antibiotic and incu-
bated overnight on a shaker at 378C. On the following day,
10 mL of the overnight culture was inoculated in 1 L of fresh
LB or 2YT supplemented with antibiotics. The cultures were
grown on a shaker at 378C until the OD600 was at least 0.9.
After inducing with 1 mM IPTG, cells were further cultured
at 428C or 378C in a shaker for 4 h, or overnight, respectively.
Induced cells were collected following centrifugation at
4000 g, 48C, for 10 min. Fractions of wet induced cell pellets
were resuspended in phosphate buffer, pH 7.4 (20 mM sodi-
um phosphate buffer and 500 mM NaCl with 10 mM imid-
azole) or 50 mM Tris buffer at pH 7.3. These buffers were
supplemented with 6 M urea in case of denaturing purifica-
tion. To minimise protein degradation, all manipulations
were done in a refrigerated chromatography cabinet. Cells
were lysed using several rounds of sonication. After each
sonication the suspension was centrifuged at 9000 g, 48C, for
30 min. Supernatants that were collected were pooled, treat-
ed with benzonase nuclease (Novagen, Merck, Nottingham,
UK) and filtered through a 0.45-mm filter before use in pro-
tein purification. Recombinant proteins were purified by
affinity chromatography (1 mL HiTrap chelating HP columns,
Amersham Biosciences, Uppsala, Sweden). The recombi-
nant proteins were eluted in 100 mM phosphate buffer, pH
7.4 with 500 mM imidazole (Sigma-Aldrich, St. Louis, MO).
Proteins were further purified with Sephadex G-75 gel filtra-
tion chromatography on an AKTA-FPLC system (Amersham
Biosciences). All protein expressions and purification steps
were checked using sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE).
Plaque purification of UB05 plaque specific
antibodies
High titre UB05 phages were used to infect XL-1 blue cells
and grown in top SOB agarose on LB plates. Phages were
grown at 378C to pinpoint plaques and then overlaid with
nitrocellulose discs impregnated with 10 mM IPTG. After an
hour of incubation, filters were lifted and washed thrice for
10 min each in phosphate-buffered saline (PBS)-tween. Fil-
ters were then blocked with 1% gelatine and washed in PBS
to remove excess blocking agent. Using a clean Petri dish,
filters were overlaid with 3 mL of a 1:40 dilution of depleted
partially immune human serum pool and incubated over-
night at 48C with intermittent rocking. The following day,
unbound antibodies were washed off with five changes of
PBS-tween and then with PBS. Next, antibodies were eluted
with rocking filters in three rounds of 1 mL volumes of
150 mM glycine-HCl, pH 2.5. The antibody eluates were
immediately equilibrated and stabilised by adding four vol-
umes of 0.6 mg/mL bovine serum albumin (BSA) in 1.5 M
Tris buffer, pH 8. They were stored diluted 1:1 in glycerol at
–208C until needed.
Immunisation of mice with UB05
Polyclonal antisera were raised in BALB/c mice that were
immunised on days 0, 21, and 30 with an emulsion contain-
ing ;50 mg of purified UB05 fusion recombinant protein in
PBS – incomplete Freund’s adjuvant (IFA) (1:1) at two sites
subcutaneously. Blood was collected prior to initial immu-
nisation and after the last boost from the tail vein. The serum
fraction was assayed for UB05 specific antibody content
using a standard enzyme-linked immunosorbent assay (ELI-
SA) as described previously (15, 16).
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blotting were performed according
to standard methods as described elsewhere (23, 24). Plas-
modium antigens from infected blood cultures, recombinant
bacteria cell extracts and purified recombinant proteins were
separated using either 5%–20% gradient or 12.5% SDS-poly-
acrylamide gels, and then analysed by staining with Coo-
massie Brilliant Blue or by immunoblotting on nitrocellulose.
Antibodies used for blotting included plaque purified UB05
human antibodies, anti-6His monoclonal antibodies (Phar-
macia), mouse anti-UB05 antibodies and human sera. Opti-
mum antibody or sera dilutions for immunoblotting were
determined empirically for each assay. Bound antibodies
were revealed by reaction with rabbit antihuman-IgG or goat
anti-mouse horse raddish peroxidise conjugates (Sigma) and
diaminobenzidine (Sigma).
Localisation of UB05 antigen
An indirect immunofluorescent antibody (IFA) test to detect
the location of the UB05 protein in P. falciparum was per-
formed on air dried films of infected red blood cell (RBC) as
described previously (25, 26). Briefly, P. falciparum strain F32
parasite culture, enriched for late stage schizonts by flotation
on 1% gelatine, were used. Mature parasite cultures were
spotted onto slides and fixed in methanol or acetone. They
were then incubated with different dilutions of purified anti-
UB05 IgG for 1 h at room temperature. Labelled chicken anti-
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Figure 1 Typical plague lifts from P. falciparum (3D7)
expression library in lambda zap vector.
The nitrocellulose lifts were probed with infected children
sera (IC) and healthy adult (HA, semi-immune) sera from a
high transmission malaria zone. Other experimental details
are given under Materials and methods.
mouse (Alexa Flour) and goat anti-chicken antibodies
(Molecular Probe, USA) diluted 1:500 in Tris Hanks (TH) were
used as secondary and tertiary antibodies, respectively.
Between incubations, the slides were washed 3 times with
PBS. The end-point titre was taken as the highest dilution
which gave specific staining against the parasites.
Growth inhibition studies
We compared the reinvasion/growth inhibition activity of the
mouse antisera to UB05, purified mouse anti-UB05 IgG and
mouse pre-immune IgG using a modified protocol previous-
ly established (25, 26). The IgG fraction from the pre-immune
and immune sera was purified using Ab SpinTrap affinity
chromatography. Briefly, target uninfected Oq erythrocytes
were washed three times in RPMI and used directly or
labelled with fluorescein isothiocynate (FITC). Labelled cells
were washed an additional 3 times in RPMI 1640 to remove
all unincorporated FITC. Invasion assays were set with syn-
chronous rings or trophozoites P. falciparum strains 3D7 and
F32 at 2% parasitaemia. Triplicate assays of each decreasing
doubling dilutions of test antibodies and malaria culture
medium were incubated in a candle jar at 378C, with a
change of medium every 24 h. After 60 h, the erythrocytes
were washed with PBS and then stained with ethidium bro-
mide or hydroethidine fluorescent vital stain to detect para-
site DNA. A total of 50,000 stained cells/assay were then
counted by flow cytometry (FACS Calibur, BD bioscience,
Franklin Lakes, NJ, USA). Percent inhibition by antibodies
was determined as w1–(proportion of target cells invaded in
presence of UB05 antibodies/proportion of target cells invad-
ed in pre-immune antibodies)x=100.
Protein determination
Protein concentrations in the chromatographic fractions
were estimated at 280 nm using an Ultrospec 1000 spectro-
photometer (Pharmacia Biotech). In all other experiments,
protein quantities were measured using standard Bradford
assay with bovine serum albumin as a standard.
Detection of antibodies to clone UB05 in human
sera
Sera samples from P. falciparum infected and uninfected
individuals in the Bolifamba endemic community were
assayed using ELISA for concentrations of UB05 specific IgG.
Five mg/mL of the purified recombinant protein was used in
these assays. Antisera from patients were assayed at a dilu-
tion of 1:100 in PBS containing 5% non-fat milk. The non-
parametric Mann-Whitney test was employed to determine
the significance of differences in antibody levels in different
patient groups at a 95% confidence limit.
Results
Differential screening of P. falciparum 3D7 library
In the primary screening experiments, a dilution of
1:150,000 of the phage library stock in SM buffer was
used. This dilution gave at least 2000 pfu per plate for
each filter. Twenty-thousand clones were screened in
ten primary screens. The anti-E. coli antibody-deplet-
ed healthy adult (HA) and IC sera employed in screen-
ing were highly reactive against crude Plasmodium
antigens using ELISA (Figure 1). A total of 63 clones
were identified by the HA pool, 37 by the IC pool and
23 by both serum pools. Twenty-six distinct clones
were picked at random from the HA clones, and ten
from the IC clones for further rounds of screening.
After the fourth round of screening, 11 clones were
distinctly recognised only by the HA pool, and two,
coded IC 1 and IC 2 were recognised by the IC pool.
These clones remained positive on further rounds of
screening. The HA serum pool recognised 5 times
more P. falciparum antigens than the ICs pool. Thus,
nine clones preferentially recognised by the HA pool
and two by the IC pool were purified for sequencing
and further analysis.
Nucleic acid sequence analysis
Eleven isolated clones that were sequenced were
arbitrarily code-named serially from UB01 to UB11.
UB stands for University of Buea. Following their
nucleic acid sequence analyses, the HA specific
clones comprised three groups of well-aligned
sequences: group I – UB01, UB05, UB06, UB07 and
UB11; group II – UB08 and UB09, and group III – UB03
and UB10 (Figure 2). Blastn results against the P. fal-
ciparum database at NCBI confirmed the Plasmodium
origin of the clones of groups I and II. They aligned
to a regions of P. falciparum chromosomes with
group I (UB05) matching to a region of chromosome
10 predicted to code for a hypothetical protein
PF10_0372. Genomic sequences of the UB05 gene
from laboratory and wild isolates were 1062–1262 bp
long. The entire gene is comprised of four exons and
three introns containing varying numbers of TTTA,
GTAT, TATA and TTTTTA repeats. Group II sequences
showed at least 97% homology to P. falciparum
derived nucleic acid entries including mRNA for
exported antigen Ag 5.1 (PFAG51ER), a P. falciparum
circumsporozoite protein-related antigen (M11145.1)
and P. falciparum export protein EXP-1 (X05074.1).
Sequences obtained for group III were truncated frag-
ments of Plasmodium DNA that were not studied
further.
Deduced amino acid sequence analyses
The longest cDNA sequences for each group above;
UB05 (474 bp), UB09 (378 bp) and UB10 (214 bp),
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Figure 2 Multiple sequence alignments of cDNA of clones UB01-_M13_re (455 bp), UB03-_M13_re (142 bp), UB05-T3 (474 bp),
UB06-T3 (272 bp), UB07-_M13_re (366 bp), UB11-_M13_re (470 bp), UB10-_M13_re (214 bp), and UB08-_M13_re (376 bp) Ub09-
T3 (378 bp).
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Figure 3 Phylogenetic relationship of UB05 homologues in infectious protozoa.
(I) Clustal alignment of UB05 homologues indicating consensus conserved amino acids. (II) The evolutionary history of UB05
protein in protozoa inferred using the Neighbour-Joining method (1). The bootstrap consensus tree inferred from 1000 rep-
licates (2) is taken to represent the evolutionary history of the taxa analysed (2). The percentage of replicate trees in which
the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. There were a
total of 65 positions in the final dataset. Phylogenetic analyses were conducted in MEGA4 (4).
were selected for further derived protein sequence
analyses. Blastp and tBlastx results for UB09 con-
firmed the nucleic acid alignment results as found for
the derived ORF. It showed 97% homology to a frag-
ment of circumsporozoite-related antigen and 99% to
export protein-I (EXP-I). UB10 translated into a 56-aa
peptide fragment homologous to the C-terminal of
Plasmodium berghei strain ANKA hypothetical pro-
tein (PB108231.00.0). This protein belongs to the class
of unconventional myosins found in all Plasmodia
and other organisms. The UB05 deduced amino acid
sequence was homologous to 14 other protein
sequences entries in databases. The most significant
matches comprised derived apicomplexan ORFs
from Plasmodium spp. (PF10_0372, PB000898.01.0,
PC000827.00.0, PY04877), Clostridium spp. (cgd2_
1690, Chro.20183), Theileria spp. (TP04_0076, TA07565),
Toxoplasma spp. and Bebesia spp. genomes or ESTs,
while two statistically insignificant matches were to
fragments of yeast (TIM21) and mycoplasmal proteins
(mhp478). The amino acid sequences of eight homo-
logues are aligned in Figure 3. The sequences are
highly conserved between species within each of the
protozoa genera. Some amino acid positions were
conserved absolutely or by biochemical character
between all eight species. They included particularly
(numbering for UB05) RFLD (aa9–12), F19, L28, L31,
E33, RLFPF (54–58) and from N64 to D83. The Plas-
modium spp. sequences had a conserved RDKKK
(116–119). Except for the sequence from P. yoelli yoel-
li that was truncated (30 amino acids), all the sequenc-
es were predicted by SignalP and Psort programmes
at high probabilities to have an uncleavable N-termi-
nal leader/signal peptide at least 25 amino acids long,
otherwise described as a signal anchor. Other pre-
dicted conserved features included two transmem-
brane helices sandwiching an absolutely conserved
RLFPFK loop, two or three C-terminal protein kinase
C phosphorylation signals (SLK, SSK, SRK), an N-
glycosylation signal NLTH (64–67) and a possible
myristolation site GLKDSR (90–95). All absolutely
conserved amino acids were located within the N-ter-
minal transmembrane helices and the loop. The
sequences were also predominantly charged at the C-
terminal with relatively higher proportions of lysine
(K), arginine (R), aspartic acid (D), glutamine (Q),
asparagine (N) and glutamic acid (E). Phylogenetic
analysis of the orthologues showed that the sequenc-
es clustered into three major clades constituting the
various genera Plasmodium, Clostridium/Toxoplasma
and Theilera/Babesia.
Expression and purification of recombinant UB05
The UB05 ORF was cloned into various expression
vectors and transformed into E. coli strains for expres-
sion and purification. As expected, induction of the
UB05 ORF varied depending on the vector, the host,
induction conditions and whether the sub-cloned
insert was truncated to code for the protein without
the signal peptide or for the complete protein. Suc-
cessful protein inductions with 2 mM IPTG at 428C for
5 h or overnight could be achieved only for the trun-
cated fragment cloned into the pEXP5NT to express a
14-kDa fusion polypeptide in BL21 (DE3)pLys (Figure
4). Low levels of expression of the truncated recom-
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Figure 4 Expression and purification of UB05 recombinant protein.
The expressed recombinant proteins are indicated with arrowheads. (A) Overnight induction and purification gel for UB05
from pEXP5NT in BL21(De3)pLys showing an induced lysate (a), Ni-NTA washes (b, c) and eluates (d, e) under denaturing
conditions and same lysate ran on Ni-NTA under native conditions (f–j), molecular weight references (k). (B) Purification of
UB05 on Ni-NTA under denaturing conditions (b–g) and native conditions (h–l) from a 5 h/428C induced BL21(DE3)pLys cell
lysate. (C) Partially pure UB05 from Ni-NTA eluates (a and b) further purified on sephadex G75 gelfitration and corresponding
to ARKTA chromatograms peaks F with pure Ub05 proteins eluting at Ga and its degradation products peak Hb. (D) Induction
gel of UB05 from pETM11 in BL21; preinduced (a), induced (b); in BL21(DE3)pLys, preinduced (c), induced (d); pETM-30 in
BL21, preinduced (e), induced (f), in BL21(DE3)pLys preinduced (g), induced (h and i), pETM-30 GST induction control (j),
molecular weight reference (l). (E) Induction gel of UB05 protein from pBAD/thioTopo-TA in XL1Blue (2, 3), Novablue (4, 5).
(F, G) Spetrophotometric gelscans of recombinant UB05 separated by SDS-PAGE in the absence (F) and (G) in the presence
of 2-mercaptoethanol. The arrows in A–E show the position of recombinant UB05 on SDS-PAGE and on F shows its position
on a gelscan.
Figure 5 Description of UB05 gene.
(I) Schematic representation of the coding region of UB05
gene (PF10_0372) on P. falciparum chromosome ten show-
ing regions of introns, exons and repeats. (II) Amplification
of UB05 from DNA of field isolates of P. falciparum infected
blood. The arrows indicate samples with a single 500 bp
amplicon (a), two amplicons of 500 and 285 bp amplicon (b),
and a single amplicon of 285 bp (c).
binant could also be achieved as a fusion with GST
from pETM-30 in BLR, BL21 and BL21(DE3)pLys fol-
lowing induction with 2 mM IPTG at cell densities
)1.0 OD600 and a further 5 h of culture at 378C (results
not shown). The recombinant UB05 protein formed
inclusion bodies and could be purified from induced
cultures by a combination of denaturing Ni-NTA met-
al chelate chromatography and sephadex-G75 gel
filtration in the AKTA system. Alternatively, homo-
geneous UB05 recombinant proteins could be
obtained by eluting from SDS gel slices of fraction-
ated eluates from His-trap chromatography. The yield
of UB05 antigen after purification was calculated to
be 5 mg protein/L of culture.
Amplified nucleic acid sequences of UB05
from field isolates
All malaria infected blood samples analysed were
positive for P. falciparum by PCR, with two from
Kumba showing mixed infections of both P. falcipa-
rum and P. malariae. Primers specific to a 285-bp
truncated fragment of UB05 ORF (exons 2 and 3) suc-
cessfully amplified 285 bp and 500 bp bands from
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Figure 6 Antibody reactivity of UB05 in Western blots.
(A) A 38-kDa band recognised by UB05 plaque purified anti-
bodies in malaria P. falciparum crude blood culture antigens.
(B) Reaction of UB05 recombinant protein with different sera:
1) Anti-His antibody; 2) mouse preimmune serum; 3) mouse
immune serum; 4) normal human serum; 5) human malaria
serum and 6) no serum. M designates protein molecular
weight markers.
Figure 7 Localisation of UB05 antigen.
Air dried smear of P. falciparum F32 infected-RBC immuno-
stained for UB05 antigen. The UB05 antigen reaction (green)
and nucleus (red) were revealed with ALEXA FLOUR conju-
gated to chicken anti-mouse, Goat anti-chicken and ethidium
bromide in that order. Each box represents a single field
taken for (A) the parasite pigment; (A) nuclei; (B) UB05; (C)
overlap of A and B; (D) dispersed merozoites stained for
UB05 after acetone fixation.
genomic DNA of wild isolates (Figure 5). UB05 prim-
ers allowed for the amplification of 31 out of the 68
samples analysed from Bolifamba, representing
45.6%. Of these, 17 (54.8%) displayed both the 500 bp
and 285 bp bands. All 81 samples analysed from chil-
dren in Kumba amplified as above with 60% of the
samples positive for double amplicons of 285 bp and
500 bp. Change of amplification conditions to lower
or higher MgCl2 concentrations and lower template
amounts did not lead to a single band. An increase in
annealing temperature )628C resulted in amplifica-
tion failure. Nucleic acid sequence data obtained from
two isolates from Bolifamba revealed both amplicons
translated into an ORF homologous to the isolated
UB05 from the 3D7 P. falciparum cDNA library.
Length polymorphisms due to indels and repeats in
the introns were also seen upon further analysis of
sequences of 30 wild isolates and database entries for
sequenced laboratory isolates. The genomic sequenc-
es ranged from 1062 bp in P. falciparum 3D7 to
1262 bp for HB3 strain. No DNA polymorphisms were
observed within exons of the sequences analysed.
Western blotting
To identify the UB05 protein in field isolates, crude
extracts of red blood cells infected with P. falciparum
were separated using SDS-PAGE, transferred onto
nitrocellulose and probed with plaque purified anti-
bodies to UB05. The UB05 specific antibodies were
purified from semi-immune adult human sera as
described. These antibodies recognised a 38,000-
protein band in P. falciparum crude antigen extracts
(Figure 6). The purified recombinant protein was
immunogenic in mice and generated UB05 antibod-
ies. To further authenticate the presence of natively
translated UB05, the mouse antisera were employed
in immunoblots as above. No bands could be
observed with mouse pre-immune sera, demonstrat-
ing the specificity of the antibodies. The purified
recombinant antigen reacted with antibodies from
sera of both IC and adults, confirming its antigenicity
in humans. Recombinant UB05 did not react with
normal human sera from healthy Americans who had
never visited a malaria endemic area, indicating that
prior exposure to malaria parasites was necessary for
immune reactivity of the antigen.
Localisation of UB05 antigen
The UB05 antibodies reacted positively in immuno-
fluorescence assays, uniformly staining P. falciparum
schizonts and dispersed merozoites (Figure 7).
Growth inhibition studies with UB05 antibodies
The mouse UB05 antiserum was shown to be more
inhibitory (;50%) to erythrocyte invasion by P. falci-
parum 3D7 merozoites at higher titres compared to
mouse pre-immune serum in preliminary reinvasion/
inhibition assays (Figure 8). Similar assays with
exhaustively dialysed sera and 50 mg/mL of purified
anti-UB05 mouse antibodies showed moderate inhi-
bition in vitro (data not shown).
Differential reactivity of UB05 with IgG
To further study the role of UB05, we examined the
serum concentrations of IgG antibodies to UB05 as a
function of subject age, parasite density and febrile
status. The results are presented in Figure 9. It can be
seen in Figure 9A that IgG concentrations to UB05
were significantly higher (p-0.05) in adults compared
with children. Adults in the fourth decade tended to
have higher anti-UB05 IgG concentrations than those
in the third decade, but the differences were not
significant (results not illustrated). There was no sig-
nificant difference between the antibody concentra-
tions of the non-parasitised and parasitised adults,
although the former tended to be higher. Correlation
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Figure 8 Growth inhibition studies with UB05 antibodies.
Inhibition of erythrocyte invasion by P. falciparum cultured in different dilution of mouse UB05 antiserum; (I) counted by flow
cytometry; (II) by microscopy.
Figure 9 Differential reactivity of UB05 with IgG.
(A) Age stratified IgG responses to UB05. The children’s group (IC and HC) comprise individuals of 2–5 years old and the
adult group (IA and HA) individuals of 18 or older. IC, infected children, positive for P. falciparum; IA, infected adults positive
for P. falciparum; HC, healthy children negative for P. falciparum; HA, healthy/semi-immune adults, negative for P. falciparum.
The number of subjects studied per group were: ICs29; IAs27; HCs25 and HAs31. (B, C) Effect of parasitaemia on IgG
levels to UB05. Parasitaemia was calculated as described under Materials and methods expressed as parasite (P. falciparum)
counts/mm3. (D) Effect of malaria fever status on IgG responses (OD406). qThe bars indicate the arithmetic mean OD values
of infected children with fever (ICF); healthy children without fever (HCNF); infected adults with fever (IAF) and healthy adults
without fever (HANF). The number of subjects studied was as follows: ICFs22; HCNFs7; IAFs12 and HANFs14. Less than
five designates children’s group aged 2–5 years and )18 designates adult group aged 18 years or older.
between antibody concentrations and parasitaemia in
infected individuals showed an inverse and propor-
tional relationship between parasite density and anti-
UB05 IgG antibody concentrations. Both children and
adults with high anti-UB05 IgG had low or non-detect-
able parasitaemia (Figure 9B and C). A similar ten-
dency was seen with the febrile status defined as a
body temperature of 37.58 or higher. In fact, antibody
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concentrations in the febrile group were significantly
(p-0.05) lower than in the group with normal body
temperature (Figure 9D). However, we found no cor-
relation between the anti-UB05 IgG concentrations
and the presence of splenomegaly or anaemia.
Discussion
This investigation is the first to describe the involve-
ment in host-parasite inter-play of a P. falciparum
antigen termed UB05 (Gene Bank ID DQ235690) that
was previously listed as a hypothetical protein of
unknown function (8). The cDNA and deduced amino
acid sequences of UB05 are identical to a portion of
published P. falciparum 3D7 chromosome 10 genomic
DNA and the corresponding open reading frame of
the hypothetical protein PF10_0372, respectively (8).
Clone UB05 was strongly reactive to antibodies from
semi-immune adults. It consistently representedmore
than 50% of clones preferentially reactive to semi-
immune adults following repeated screening experi-
ments. ‘Preferential reactivity’ is used here to indicate
that adults reacted more frequently with higher level
antibodies than children (Figure 9). It is possible that
the absence of reactivity to the selected HA clones by
IC antibodies could be due to low titres or quality of
clone specific antibodies, and not their absolute
absence. However, due the dominance of UB05 in our
screening panel, its identity to PF10_0372 (predicted
in the TDR targets database to be in the top 93.9% of
antigenic Plasmodium genes) and the coisolation of
known dominant antigens, we considered it worthy of
further investigation.
Searches within protein databases identified homo-
logues of UB05 protein in other Plasmodia as well
as other infectious protozoa: Cryptosporidium, Toxo-
plasma, Theilera and Babesia. This suggested that the
isolated clone belongs to a conserved gene family in
these infectious apicomplexans (Figures 2 and 3).
Apart from the P. yoelli sequence that was truncated,
homologues from all the species were predicted to
have maintained conserved topological patterns, such
as an N-terminal signal leader, two transmembrane
domains, sandwiching an absolutely conserved loop
and a highly charged C-terminal with multiple protein
kinase C phosphorylation sites. It is possible that the
isolated UB05 and its homologues play similar roles
in these protozoan parasites. If so, this may allow for
future investigation into its protective role in animal
models. Proteome and transcriptome data on PlasmoDB
showed maximum expression of the protein on tro-
phozoites (27). As shown in Figure 7, UB05 antigen is
also expressed in schizonts and segmented merozo-
ites. These blood stages of Plasmodium infection
remain the primary targets for vaccine development.
Therefore, UB05 may be part of immunogenic anti-
gens relevant for the development of immunity in nat-
ural infection.
The conserved topology of UB05 is not uncommon
for Plasmodium proteins. In fact, 31% (1631) of the
predicted proteins of the P. falciparium genome have
one or more transmembrane domains, and 17.3%
possess putative signal peptides or signal anchors (8).
Many proteins with such mophologies, for example
export protein-1, have been shown to be exported to
the surface or to cell organelles like the apicoplast and
parasitophorous vacuole membrane, where they can
be involved in physiological processes as well as
immune interactions (28). Considering that our inves-
tigation also identified the immunogen, Exp-1 (UB09),
this indirectly indicates that the UB05 antigen and its
family of protozoan homologues could be dominant
antigenic determinants in malaria. Prediction of an
absolutely conserved UB05 loop (RLFPF) by the anti-
genic mapping software at Bcipep as a B cell
epitope also suggests the antigenicity of the family.
Furthermore, structural predictive analysis of the
sequence following Psi-blast alignments against
resolved protein structures in protein database (PDB)
revealed possible folds similar to those of both intra-
cellular and cell surface membrane proteins including
translocase, ATPase subunit and receptors. These
couple to the presence of three potential protein
kinase C sites at the C-terminus, and might implicate
the molecule in some kind of intra/intercellular sig-
nalling via phosphorylation.
Primers specific to the open reading frame of UB05
were used to amplify fragments of P. falciparum
genomic DNA isolated from the blood of infected indi-
viduals in Cameroon. These amplicons were further
shown by sequencing to be identical to the isolated
clone and its Pf10_0372 homologue of P. faciparum
choromosone 10. However, the occurence of a double
amplicon, despite the extreme strigency of the PCR
conditions, indicated the possibility of polymor-
phisms. Sequencing of genomic DNA fragments of
UB05 from wild isolates confirmed the size polymor-
phisms to be determined by indels and repeats in
introns only. This further indicates that the failure of
some wild isolates in PCR could have been due to
indels in primer binding sequences. Sequences of
wild isolates from Cameroon and five laboratory
adapted isolates in PlasmoDB did not show nucleo-
tide variation within exons, thus undermining the pos-
sibility of sequence polymorphisms (Figure 5). A
desirable characteristic of some successful vaccine
candidates is that they should be highly conserved
and less susceptible to allelic discrimination and
selection by the immune system. Our study indicated
only two size alleles of UB05 and complete conser-
vation within exon sequences in field isolates from
two distinct malaria zones. Hence, the UB05 protein,
in contrast to some leading polymorphic vaccine can-
didates, such as merozoite surface protein (MSP) – 1
and 2 and PfEMP, is relatively well conserved (29).
The small size of the UB05 protein and the strong evi-
dence of B-cell epitope conservation across infectious
protozoa indicate that epitope polymorphism due to
selective immune pressure in unlikely. Such immune
pressure and selection are known to be responsible
for genetic variation in candidate vaccine antigens
and many other surface proteins amongst isolates of
Plasmodium (30).
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Plaque purified human antibodies to UB05 reacted
specifically with a 38-kDa protein band (Figure 6),
which was higher than the 13.8 kDa predicted weight
of the 119 aa long ORF. The sequenced UB05 cDNA
was complete from start codon to a polyadenylated
region, and the genomic sequences fromwild isolates
showed no indels within exons. Thus, the size differ-
ence may be due to abnormal migration of UB05
protein in SDS-PAGE. Such aberrant migrations in
SDS-PAGE observed for other proteins have been due
to aggregation, post-synthetic modifications, post-
translational cleavage, splice variants and features,
such as lysine and acidic amino acid rich clusters at
the c-terminal (31, 32). Some of these features charac-
terise the UB05 protein and sequence and may be
responsible for this abnormal PAGE migration of the
protein in crude Plasmodium lysate.
A key requirement for a protective malaria antigen
is that it should elicit strong immune responses in
protected subjects. These responses need to be long-
lasting and broadly effective in controlling parasitae-
mia or clinical manifestations of infection. UB05 was
isolated using antibodies from semi-immune adult
residents of a high malaria transmission zone (Figure
1). Like most described malaria vaccine candidates,
sero-epidemiological studies revealed significantly
higher IgG antibody concentrations in semi-immune
adults than highly susceptible children (Figure 9A and
D). As was the case with crude P. falciparum extracts,
specific antibodies to UB05 increased gradually dur-
ing the first two decades of life, attaining a plateau
around the second and third decades (15). It is now
generally accepted that IgG antibodies play a key role
in the development of protective immunity to malaria
that develops with age (33, 34), not withstanding the
participation of cellular factors (35–37). The age
dependent increase in IgG antibodies to UB05 is com-
patible with the build-up of protective immunity
against malaria. However, significantly higher anti-
UB05 IgG titres in a few children indicate that other
factors contribute to the stratification of the antibody
responses in the endemic population. The inverse
correlation of antibody concentrations to parasitae-
mia suggests that UB05 antibodies may be involved
in blocking P. falciparum asexual stage multiplication
or clearing them from circulation, although this
remains to be specifically demonstrated (Figure 9B
and C). Preliminary assessment of anti-parasite activ-
ity in vitro in reinvasion/growth inhibition assays
using rabbit anti-UB05 antibodies showed marginal
levels of invasion inhibition of merozoites. This sug-
gests that antibodies to UB05 in the endemic popu-
lation may be involved in limiting parasite invasion of
erythrocytes. Furthermore, the absence of fever in
parasitised subjects with high concentrations of anti-
UB05 antibodies suggests a role for UB05 in limiting
clinical malaria. The correlation between higher
concentrations of antibodies against malaria with
reduced parasitaemia and morbidity has been shown
for a number of vaccine candidates including the
serine rich antigen (SERA) and MSP3 (38, 39). The
direct mechanism of action of these specific antibod-
ies in reducing fever, even in the presence of malaria
parasites, remains to be determined. However, the
presence of these anti-UB05 antibodies in the absence
of fever allow for the possibility that UB05 reactivity
could be a marker of protective immunity against
malaria.
In conclusion, the present finding suggests that
UB05 is a marker of protective immunity to malaria
that deserves further investigation towards UB05-
based vaccines.
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